Newsletter · · Ashutosh Agarwal

Lilly's Twelfth Deal of 2026 Defines the Patent Cliff M&A Wave - The Biotech Patent Cliff & M&A - Week of July 24, 2026

The Biotech Patent Cliff & M&A newsletter for the week of July 24, 2026. Eli Lilly's purchase of atai/Beckley was its 12th acquisition of the year, roughly $23 billion of upfront M&A that a biotech-insider panel dubbed the 'Amazonification of pharma,' while a BMO analyst put price targets on the cliff trade (Merck over Bristol, Lilly over Novo) and a fund manager flagged a reopened IPO window as a second exit for small biotechs.

The Biotech Patent Cliff & M&A

Week of July 24, 2026: Lilly's Twelfth Deal of 2026 Defines the Patent Cliff M&A Wave

Most of the patent-cliff story is about companies playing defense: Merck bracing for Keytruda, Pfizer sprinting to replace what falls off patent. This week the loudest voice in biopharma was the one company with no cliff at all. Eli Lilly bought a psychedelics developer, and buried in the coverage was a number that reframes the whole M&A wave: it was Lilly's twelfth acquisition of the year, bringing its 2026 outlay to roughly $23 billion in upfront cash, before a single milestone payment. The cliff-facing giants buy because they have to. Lilly is buying because it can.

TL;DR

  • Lilly is on a once-a-month buying spree. Its purchase of atai/Beckley, about $3.8 billion, split $2.8 billion cash up front and $1 billion in a milestone-linked CVR, is deal number 12 this year and takes Lilly's 2026 upfront M&A spend to around $23 billion. A biotech-insider panel called it the "Amazonification of pharma": Lilly is pushing into psychedelics, infectious disease and neuroscience all at once, years ahead of any pressure on its obesity franchise.
  • A sell-side analyst put real price targets on the cliff trade. BMO's Evan Siegerman told CNBC he prefers Merck over Bristol and Lilly over Novo, with a Buy on Merck (target 142) built entirely on management's credibility in replacing the ~$30 billion Keytruda loses at the end of the decade, and an Outperform on AbbVie (target 300) after its bolt-on of Apogee.
  • A biotech fund manager says the exit door has swung both ways open again. Roughly 15% of her fund's value was taken out in M&A last year, and another 15% already this year, at the halfway mark. Just as important, the IPO window that was "closed in effect" for three years is now "very much open," giving small biotechs two live exits instead of one.

What's new

Lilly's twelfth deal, and what the pace really means. The concrete news was Lilly buying atai/Beckley, a psychedelics developer, for about $3.8 billion, "2.8 billion upfront and 1 billion linked to a CVR," as the panel on Biotech Hangout laid it out. (A CVR, or contingent value right, is essentially a written IOU: the seller only collects that extra billion if the drug hits agreed targets, a way to bridge the gap when buyer and seller disagree on how an unproven medicine will pan out.) The lead asset is a fast-acting, nasally administered psychedelic for treatment-resistant depression, and Lilly is buying it ahead of the key trial readout, "a strong and aggressive bet on their part," as one panelist put it.

The number that matters, though, came from BioCentury This Week, where the editors noted this is "the 12th acquisition so far this year for Lilly. That brings its total outlay on M&A alone to around $23 billion in upfront payments." It's Lilly's second big neuroscience takeout of the year, after it "bought Centessa for $6.3 billion upfront, along with a $1.5 billion CVR" to move into narcolepsy. Twelve deals in seven months is not opportunism, it's a strategy.

The Biotech Hangout crew, a panel of biotech operators and investors, so treat this as insider color rather than sell-side opinion, gave that strategy a name: the "Amazonification of pharma." As one host put it, Lilly "seem[s] to be going in every possible area of pharma… a couple of months ago, they did three deals almost back to back in infectious diseases. And then now here, this is the third" push outside neurodegeneration. Why the urgency from a company whose obesity drugs are still booming? Because, the panel argued, that boom won't last forever, there will "inevitably" be "some kind of plateau or pressure on their obesity franchise," maybe a decade out, and Lilly would rather build the next act now than "let it ride." The admiring verdict: "boy, they're just showing nothing less than incredible urgency around that future build… It's just so smart."

There's a bigger idea underneath. The panel pointed to an Economist piece titled "Lilly reinventing the pharma business," describing CEO Dave Ricks trying to turn Lilly from "a traditional drug maker to something that's frankly closer to a tech company," shifting toward preventing disease rather than treating it, and using its Lilly Direct telehealth service to sell straight to consumers, "effectively going around the PBMs" (the pharmacy-benefit middlemen who sit between drugmakers and patients). This is what the strongest company in the sector does with a war chest and no cliff to fear: it rewrites the playbook while everyone else patches holes.

The cliff trade, with price targets attached. On CNBC's Power Lunch, BMO's head of healthcare research Evan Siegerman, a sell-side analyst, so this is opinion with a book behind it, turned the patent-cliff theme into specific calls as earnings season opens (Bristol-Myers reports first, next week). His framing: "You have to pick the right stocks… some of the big pharma names are set up better than others. We like Merck over Bristol… I prefer Lilly over Novo."

His Merck call (Buy, target 142) is the purest cliff bet on the board. The whole thesis, in his words, is "real credibility for management and how they're solving for the Keytruda LOE at the end of the decade. This is their massive cancer drug, $30 billion in sales that they're going to have to replace. Not all of it, part of it." ("LOE" is loss of exclusivity, the day cheap copies can legally compete and a blockbuster's sales fall off a cliff.) He credits "acquisitions, internal development, and putting together a portfolio of assets" for giving Merck a shot at "stability in the P&L and potentially growth" through the event. He also flagged a newer Merck card: enlisitide, "the pill version of Repatha," an oral cholesterol drug that could reach a huge everyday market.

On AbbVie (Outperform, target 300), Siegerman leaned on this week's own M&A: "AbbVie just announced the deal for Apogee to expand their I&I franchise" (immunology and inflammation), on top of its existing strength in Skyrizi and Rinvoq. He waved off the worry that J&J's competing inflammation drugs are stealing share, "we're not seeing any major issues in the scripts." The through-line across both names: the market is now willing to pay up for management teams it believes can out-run their own cliffs, and the way they do it is by buying.

A fund manager says the exit window is wide open, both doors. The most useful buy-side view came from MoneyWeek Talks, where a biotech fund manager (named Elsa) described what the deal wave looks like from inside a portfolio: "this last year, 15% of our fund was acquired of NAV. This year to date, 15%. Already. And we're in halfway." (Read: takeovers have carried off a chunk of her holdings equal to 15% of the fund's value in each of the last two years, an extraordinary hit rate.) The driver, she said, is simply "the need from pharma who has lots of cash and ability to leverage up… to grab promising things."

Her second point is the one worth filing away. For years a small biotech had really only one realistic exit, getting bought, because "the IPO window has been closed in effect for the last sort of three years." That, she says, "has very much changed." Listing on the stock market "is now seen as an exit again… the window is very much open now." Two live exits instead of one changes the negotiating math: a target that can credibly threaten to go public alone can hold out for a richer takeover price. It also means the froth isn't only in M&A, the public financing spigot is back on.

The debate

Here's the honest state of play: this week's podcasts were almost entirely one-sided, and bullish. Nobody made a serious bear case, and, notably, nobody even mentioned the FTC or antitrust risk that dominated the conversation just last week. That silence is itself information.

The bull case now rests on three legs, all voiced clearly this week. First, the buyers have bottomless resources and are using them with urgency, Lilly's twelve deals are the loudest proof, but the whole sector is up "80 percent over the past year," as Power Lunch noted. Second, the political overhang that scared investors has, in the buy-side telling, simply evaporated: MoneyWeek's manager ticked off "16 pharma deals with major pharma in the administration," and declared the drug-pricing fight and the tariff fight both "done… off the agenda." Third, sellers finally have leverage again, because the reopened IPO window gives them a credible alternative to selling.

The bear case went unspoken, and that's the thing to watch. Last week a former banker warned that drug pricing (the "most favored nation" push to force US prices down toward what other rich countries pay) was the one flashpoint that could still gum up the deal machine. This week the buy-side treated that same risk as settled and behind us. Someone is going to be wrong. When a market this hot stops even articulating what could go wrong, the absence of a bear is not comfort, it's the setup. To be clear: no guest this week argued pharma is overpaying or that these drugs won't work. The risk isn't in the deals; it's in the complacency around them.

There was also a quieter structural read worth noting, from the same insider panel. A big share of biopharma's new molecules now originate in China, BioCentury reported that "40% of new [molecular entities] originating from China are now first in class." One asset-hunter on the panel called China "a little bit of a smoke screen or a red herring" for a deeper shift: making new antibodies and small molecules is getting faster and cheaper everywhere, so ideas move "from an idea to an experiment" at remarkable speed. His reassuring coda for US investors: whoever invents a drug anywhere still wants it "studied in late stage trials in the US and approved for use here," largely because "our high pricing for drugs" makes the US the place innovation gets paid, "so innovation around the world winds up benefiting us." The uncomfortable flip side he left implicit: that entire advantage rests on US prices staying high, which loops right back to the pricing fight everyone just declared over.

The names in play

The specific takeout candidates this week came from the MoneyWeek fund manager, so treat these as one professional investor's book, not confirmed deal chatter.

  • Madrigal Pharmaceuticals, her clearest live target. Its drug Rezdiffra treats MASH (fatty-liver disease driven by weight, not alcohol, a huge and until-recently untreated US market), and after "a stellar launch in a disease that had no treatments… at the moment, they own that market." Her verdict: "It is a name, actually, that we think could be acquired."
  • Soleno Therapeutics, the one that already got taken out, and a template for the pattern. It made a drug for Prader-Willi syndrome, a rare genetic disorder that leaves children with an insatiable, dangerous appetite. "This company launched their drug a year or so ago. The sales launch was so strong that obviously it attracted big pharma interest and the company was acquired" (she named the buyer as Neurogrid). Strong launch in a rare disease with no competition equals a fast bid, that's the takeout recipe in one story.
  • Vera Therapeutics, her value pick on the cusp of a catalyst. A rare kidney-disease (IgAN) drug "just over $2 billion in market cap… on the cusp of approval" via the FDA's accelerated pathway, expected this year, with "peak sales could be $1 to $2 billion… in 2030, 2031." Her read: "looking very attractive valuation at the moment."

On the buyer side, the investor panel on Telltales drew a sharp line between two ways of dealing with a cliff. They like Vertex as the good example: "on the smaller side of big pharma… They've grown there by being good capital allocators," and its recent acquisition (whose lead drug, Palsonify, won approval late last year) "would be a quite good acquisition" if it hits its goals, Vertex is "allocating for growth."

Pfizer is the cautionary opposite. The panel's memorable line: Pfizer is "in a constant cycle on the hamster wheel of replacing their pipeline or replacing drugs that are falling off patent, having to do a lot of acquisitions, that's not a good place to be… playing defense trying to replace revenue that's falling away." They also noted, pointedly, that Pfizer is "the only one with debt on" among the big-pharma names they screen, a reminder that not every cliff-facing giant has Lilly's or Merck's firepower to buy its way out. They rounded it out with a preference for Regeneron over the crowd, "trading at a lower multiple today," with strong management and pipeline, "repriced for the future" as its two flagship drugs face competition.

Read-throughs

  • Biosimilars are being played as channel plays, not price wars. The most concrete biosimilar idea of the week was small: the Telltales panel described micro-cap Harrow, which is "introducing a biosimilar" of Regeneron's eye drug Eylea so it can bundle it with the topical anesthetic surgeons use before an eye injection and sell the package into ophthalmology practices. The logic is that big pharma "don't want to waste their time with these products that don't make much money," leaving a sales-force-driven niche for a small player who "nobody knows ophthalmology better than." The read-through for anyone underwriting biosimilar makers: at the small-cap end, the edge is distribution and bundling, not undercutting on price.
  • A SMID operator's take on the GLP-1 aftermarket. On Biotech 2050, Sparrow Pharmaceuticals CEO Robert Jacks (an operator, not an analyst) made a point that matters for the whole obesity/diabetes complex: even with GLP-1s everywhere, "about half of people with type 2 diabetes are not adequately controlled." His lean, 11-person company is developing a cortisol-pathway drug meant to work alongside GLP-1s for those non-responders, a reminder that the "everyone's on a GLP-1" narrative leaves a large unmet-need market that becomes the next round of assets big pharma will shop for.
  • Bankers and CROs, no distinct call this week. A once-a-month Lilly deal pace obviously keeps the advisory banks busy, but no guest voiced a specific, investable thesis on a named bank or contract research organization.

What changed

Last week the newsletter was built on hard, fresh data, a deal-tracker showing billion-dollar takeouts now close in 46 days versus 112, a re-sized $230 billion patent cliff, and a former banker making a friendly FTC the centerpiece of the bull case. This week there was no new deal-tracker math and, tellingly, not one mention of the FTC or antitrust from anyone. The conversation moved from the mechanics of why deals close so fast to the spectacle of who's spending, with Lilly's twelve-deal, ~$23 billion year as the headline.

Two shifts are worth marking. First, the risk narrative didn't just soften, it went quiet. Seven days ago drug pricing was named as the single thing that could slow the wave; this week the buy-side declared pricing and tariffs flatly "done." That's a more confident, and more complacent, market than the one talking last week. Second, a genuinely new bullish leg appeared: the reopening of the IPO window as a second exit for small biotechs, which strengthens sellers' hands and adds fuel that isn't dependent on the takeover bid alone. The deals keep coming, but the sector has stopped arguing with itself about what could go wrong, and that's the part worth keeping an eye on.